Ginkgo Bioworks Holdings, Inc.

DNA ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — Ginkgo Bioworks Holdings, Inc.

Total Moat Score 10 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 2 / 5 Ginkgo explicitly discloses that no single patent or patent family is essential to its business, relying instead on trade secrets and a proprietary 2.7-billion-gene metagenomic library and functional-performance database that are valuable but legally far weaker than patent protection.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 2 / 5 The automated Reconfigurable Automation Cart foundry theoretically lowers the marginal cost of each new engineering program versus manual in-house R&D, but heavy fixed costs and a 25% revenue decline in 2025 show the cost advantage has not yet translated into profitability.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 1 / 5 Ginkgo competes primarily against customers' own in-house R&D capability and must prove cost/speed advantages to win business at all, leaving little room to charge premium prices, and customer concentration further weakens its negotiating position.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 2 / 5 Management's thesis is that more customer programs generate more data that makes the platform smarter and cheaper for the next customer, a genuine but still largely unproven data network effect given the company's recent revenue decline and heavy reliance on a small customer base.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 Customers engage Ginkgo on a per-program, service-fee basis rather than embedding deeply integrated, hard-to-replace infrastructure, so switching to an in-house team or a competing CRO/platform between programs carries relatively low structural friction.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 2 / 5 The capital intensity of building and maintaining an automated synthetic-biology foundry at scale creates some barrier to new entrants, but well-capitalized technology and life-science tools companies (Thermo Fisher, WuXi Biologics) could plausibly build competing capacity, limiting the durability of this advantage.